An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia

Journal of Clinical Oncology

Volumn 21, Issue 24, 2003, Pages 4546-4552

  Rudin, Charles M ^a   Cohen, Ezra E W ^a   Papadimitrakopoulou, Vassiliki A ^a   Silverman Jr , Sol ^a   Recant, Wendy ^a   El Naggar, Adel K ^a   Stenson, Kirsten ^a   Lippman, Scott M ^a   Hong, Waun Ki ^a   Vokes, Everett E ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; KI 67 ANTIGEN; ONYX 015; PROTEIN P53; VIRUS ANTIBODY; VIRUS VACCINE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MOUTH CANCER; MOUTHWASH; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEROLOGY; TREATMENT RESPONSE; TUMOR BIOPSY; VIRUS REPLICATION; ADENOVIRUS; ADULT; AGED; CLINICAL TRIAL; FEMALE; IN SITU HYBRIDIZATION; MALE; MIDDLE AGED; MOUTH HYGIENE; MOUTH TUMOR; NONPARAMETRIC TEST; PRECANCER; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADENOVIRIDAE; ADMINISTRATION, TOPICAL; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IN SITU HYBRIDIZATION; MALE; MIDDLE AGED; MOUTH NEOPLASMS; MOUTHWASHES; PRECANCEROUS CONDITIONS; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; VIRAL VACCINES;

EID: 1542438707     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.03.544     Document Type: Article

References (43)

1. Jemal A, Murray T, Samuels A, et al: Cancer statistics, 2003. CA Cancer J Clin 53:5-26, 2003
2. Anderson WF, Hawk E, Berg CD: Secondary chemoprevention of upper aerodigestive tract tumors. Semin Oncol 28:106-120, 2001
3. Lippman SM, Hong WK: Second malignant tumors in head and neck squamous cell carcinoma: The overshadowing threat for patients with early-stage disease. Int J Radiat Oncol Biol Phys 17:691-694, 1989
4. Day GL, Blot WJ: Second primary tumors in patients with oral cancer. Cancer 70:14-19, 1992
5. Slaughter DP, Southwick HW, Smejkal W: "Field cancerization" in oral stratified squamous epithelium. Cancer 6:963-968, 1953
6. Vokes EE, Weichselbaum RR, Lippman SM, et al: Head and neck cancer. N Engl J Med 328:184-194, 1993
7. Jones AS, Morar P, Phillips DE, et al: Second primary tumors in patients with head and neck squamous cell carcinoma. Cancer 75:1343-1353, 1995
8. Chung KY, Mukhopadhyay T, Kim J, et al: Discordant p53 gene mutations in primary head and neck cancers and corresponding second primary cancers of the upper aerodigestive tract. Cancer Res 53:1676-1683, 1993
9. Scholes AG, Woolgar JA, Boyle MA, et al: Synchronous oral carcinomas: Independent or common clonal origin? Cancer Res 58:2003-2006, 1998
10. Bedi GC, Westra WH, Gabrielson E, et al: Multiple head and neck tumors: Evidence for a common clonal origin. Cancer Res 56:2484-2487, 1996
11. Worsham MJ, Wolman SR, Carey TE, et al: Common clonal origin of synchronous primary head and neck squamous cell carcinomas: Analysis by tumor karyotypes and fluorescence in situ hybridization. Hum Pathol 26:251-261, 1995
12. Waldron CA, Shafer WG: Leukoplakia revisited: A clinicopathologic study 3256 oral leukoplakias. Cancer 36:1386-1392, 1975
13. Axell T: A prevalence study of oral mucosal lesions in an adult Swedish population. Odontol Revy 27:1-103, 1976
14. Sciubba JJ: Oral leukoplakia. Crit Rev Oral Biol Med 6:147-160, 1995
15. Califano J, Westra WH, Koch W, et al: Unknown primary head and neck squamous cell carcinoma: Molecular identification of the site of origin. J Natl Cancer Inst 91:599-604, 1999
16. Califano J, Westra WH, Meininger G, et al: Genetic progression and clonal relationship of recurrent premalignant head and neck lesions. Clin Cancer Res 6:347-352, 2000
17. Califano J, van der Riet P, Westra W, et al: Genetic progression model for head and neck cancer: Implications for field cancerization. Cancer Res 56:2488-2492, 1996
18. Mao L, Lee JS, Fan YH, et al: Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat Med 2:682-685, 1996
19. Brennan JA, Mao L, Hruban RH, et al: Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. N Engl J Med 332:429-435, 1995
20. Hong WK, Endicott J, Itri LM, et al: 13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med 315:1501-1505, 1986
21. Mao L, El-Naggar AK, Papadimitrakopoulou V, et al: Phenotype and genotype of advanced premalignant head and neck lesions after chemopreventive therapy. J Natl Cancer Inst 90:1545-1551, 1998
22. Lippman SM, Batsakis JG, Toth BB, et al: Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. N Engl J Med 328:15-20, 1993
23. Lotan R, Xu XC, Lippman SM, et al: Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin. N Engl J Med 332:1405-1410, 1995
24. Papadimitrakopoulou VA, Hong WK, Lee JS, et al: Low-dose isotretinoin versus beta-carotene to prevent oral carcinogenesis: Long-term follow-up. J Natl Cancer Inst 89:257-258, 1997
25. Koch WM, Brennan JA, Zahurak M, et al: p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma. J Natl Cancer Inst 88:1580-1586, 1996
26. Shin DM, Kim J, Ro JY, et al: Activation of p53 gene expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 54:321-326, 1994
27. Nees M, Homann N, Discher H, et al: Expression of mutated p53 occurs in tumor-distant epithelia of head and neck cancer patients: A possible molecular basis for the development of multiple tumors. Cancer Res 53:4189-4196, 1993
28. Cohen EE, Rudin CM: ONYX-015: Onyx Pharmaceutical. Curr Opin Investig Drugs 2:1770-1775, 2001
29. Ries S, Korn AVM: ONYX-015: Mechanisms of action and clinical potential of a replication-selective adenovirus. Br J Cancer 86:5-11, 2002
30. Heise C, Sampson-Johannes A, Williams A, et al: ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 3:639-645, 1997
31. Burgert HG, Ruzsics Z, Obermeier S, et al: Subversion of host defense mechanisms by adenoviruses. Curr Top Microbiol Immunol 269:273-318, 2002
32. Rothmann T, Hengstermann A, Whitaker NJ, et al: Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J Virol 72:9470-9478, 1998
33. McCormick F: ONYX-015 selectivity and the p14ARF pathway. Oncogene 19:6670-6672, 2000
34. Ries SJ, Brandts CH, Chung AS, et al: Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant d11520 (ONYX-015). Nat Med 6:1128-1133, 2000
35. Papadimitrakopoulou VA, Shin DM, Hong WK: Molecular and cellular biomarkers for field cancerization and multistep process in head and neck tumorigenesis. Cancer Metastasis Rev 15:53-76, 1996
36. Lippman SM, Shin DM, Lee JJ, et al: p53 and retinoid chemoprevention of oral carcinogenesis. Cancer Res 55:16-19, 1995
37. Rudin CM: Chemoprevention in oral dysplasia, in Rose BD (ed): UpToDate: Oncology. Wellesley, MA, UpToDate, 2001
38. Liede K, Hietanen J, Saxen L, et al: Long-term supplementation with alpha-tocopherol and beta-carotene and prevalence of oral mucosal lesions in smokers. Oral Dis 4:78-83, 1998
39. Jyothirmayi R, Ramadas K, Varghese C, et al: Efficacy of vitamin A in the prevention of loco-regional recurrence and second primaries in head and neck cancer. Eur J Cancer B Oral Oncol 326:373-376, 1996
40. van Zandwijk N, Dalesio O, Pastorino U, et al: EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer: For the European Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups. J Natl Cancer Inst 92:977-986, 2000
41. Hong WK, Lippman SM, Itri LM, et al: Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 323:795-801, 1990
42. Khuri FR, Lippman SM, Spitz MR, et al: Molecular epidemiology and retinoid chemoprevention of head and neck cancer. J Natl Cancer Inst 89:199-211, 1997
43. Pinto H, Li Y, Loprinzi C, et al: Phase III trial of low-dose 13-cis-retinoic acid for prevention of second primary cancers in stage I-II head and neck cancer: An Eastern Cooperative Oncology Group study. Proc Am Soc Clin Oncol 20:222a, 2001 (abstr 866)